REMEDISC Trademark
Trademark Overview
On Thursday, February 23, 2023, a trademark application was filed for REMEDISC with the United States Patent and Trademark Office. The USPTO has given the REMEDISC trademark a serial number of 97809425. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 3, 2024. This trademark is owned by Spine Biopharma, LLC. The REMEDISC trademark is filed in the Pharmaceutical Products category with the following description:
Biomedical compounds, namely, amino acids for medical purposes administered for medical therapies; amino acids for medical purposes administered by injection for treatment of spinal diseases or disorders; 7-amino acid peptide chain, namely, amino acids for medical purposes administered by intradiscal injection for the treatment of lumbar degenerative disc disease.
General Information
| Serial Number | 97809425 |
| Word Mark | REMEDISC |
| Filing Date | Thursday, February 23, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, September 3, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 9, 2024 |
Trademark Statements
| Goods and Services | Biomedical compounds, namely, amino acids for medical purposes administered for medical therapies; amino acids for medical purposes administered by injection for treatment of spinal diseases or disorders; 7-amino acid peptide chain, namely, amino acids for medical purposes administered by intradiscal injection for the treatment of lumbar degenerative disc disease. |
| Pseudo Mark | REME DISC |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 28, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Spine Biopharma, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | New York, NY 10022 |
| Party Name | Spine Biopharma, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | New York, NY 10022 |
Trademark Events
| Event Date | Event Description |
| Monday, February 27, 2023 | NEW APPLICATION ENTERED |
| Tuesday, March 14, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, November 21, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, November 29, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 29, 2023 | NON-FINAL ACTION E-MAILED |
| Wednesday, November 29, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, February 28, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, February 28, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, May 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 31, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 19, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 9, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 9, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 3, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, May 28, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, May 28, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, December 6, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, December 6, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, December 6, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
